Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Press Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2018 Archives

Dec 3, 2018
- Preliminary Anti-Leukemic Activity Demonstrates >80% Response to Treatment with Onvansertib in Combination with Low-Dose Cytarabine (LDAC) or Decitabine in Dose Escalation Phase 1b of Trial
Nov 13, 2018
New website offers visitors greater insight into the Company's focus in oncology drug development, predictive clinical biomarkers and advances in Onvansertib clinical program
Nov 1, 2018
Targeted treatment with highly-selective, oral Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, in combination with standard-of-care chemotherapy may represent a new treatment option in AML
Oct 24, 2018
New patent claims strengthen patent estate revenue Aligns with Onvansertib Clinical Development and Biomarker Strategy in AML
Oct 18, 2018
-Webcast and Conference Call for Investors and Analysts on Wednesday, October 24th at 8:30 am EDT
Oct 3, 2018
Patent agreement covers rights to develop combination therapies and identified predictive clinical biomarker across cancer types, expanding indications for Onvansertib
Sep 27, 2018
Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with decitabine in dose-escalation phase of trial
Sep 18, 2018
Company overview, update on Onvansertib clinical development program and anticipated near-term value-creation milestones
Sep 5, 2018
Target engagement and inhibition of PLK1 by Onvansertib predictive of treatment response
Aug 16, 2018
Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial
Aug 15, 2018
Onvansertib's product profile and attributes may offer the potential to provide significant clinical benefit with regard to efficacy and safety in patients with various types of cancer
Jun 27, 2018
Additional pharmacodynamic data supports inhibition of PLK1 in leukemic cells as measured by pTCTP in its Phase 1b/2 trial in Acute Myeloid Leukemia (AML)
Jun 22, 2018
William Welch has resigned as CEO and Director
Jun 21, 2018
Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and recruiting patients for Phase 2 open-label trial of PCM-075 and abiraterone acetate (Zytiga®) in metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jun 15, 2018
Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with decitabine in dose-escalation phase of trial